Skip to main content

Table 3 Overall survival (OS) and progression-free survival (PFS) for s-CPM and m-CPM patients post CRS and HIPEC

From: The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

 

No. of events/no. of patient

Median OS, (95% CI)

1 year rate, % (95% CI)

3 year rate, % (95% CI)

5 year rate,% (95% CI)

p value

Overall survival

 s-CPM

9/20

26.9 (9.8–44.5)

77.0 (43.2–92.2)

27.5 (4.5–58.4)

13.8 (0.8–44.7)

0.025

 m-CPM

25/82

45.2 (30.2–54.3)

92.1 (81.3–96.0)

62.0 (45.1–74.6)

31.2 (15.1–48.4)

 

Progression-free survival

 s-CPM

9/20

19.7 (7.7–43.2)

75.5 (41.6–91.4)

28.8 (5.2–59.1)

0

0.356

 m-CPM

45/82

30.2 (19.8–37.8)

92.2 (82.3–96.7)

39.8 (26.2–52.9)

10.2 (3.5–21.5)